These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17026795)

  • 21. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
    [No Abstract]   [Full Text] [Related]  

  • 22. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Gamboa EO; Rehmus EH; Haller N
    Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
    Reddy GK
    Clin Colorectal Cancer; 2005 Jan; 4(5):300-1. PubMed ID: 15663832
    [No Abstract]   [Full Text] [Related]  

  • 24. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
    Ryan EM; Hanly A; Morrin MM; McNamara DA
    J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
    [No Abstract]   [Full Text] [Related]  

  • 28. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
    Krieger G
    Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323
    [No Abstract]   [Full Text] [Related]  

  • 29. [A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
    Nishida K; Matsuyama T; Masuda D; Hosokawa T; Tokita H; Kakimoto M; Goto H; Yoshimura T; Koshiishi H; Okamura T
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2517-9. PubMed ID: 21224625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F; Mansueto G
    Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract]   [Full Text] [Related]  

  • 31. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
    Van Cutsem E; Bajetta E; Valle J; Köhne CH; Hecht JR; Moore M; Germond C; Berg W; Chen BL; Jalava T; Lebwohl D; Meinhardt G; Laurent D; Lin E
    J Clin Oncol; 2011 May; 29(15):2004-10. PubMed ID: 21464401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Kabbinavar F; Kozloff M
    Oncology; 2011; 80(1-2):135-7; author reply 140-1. PubMed ID: 21677459
    [No Abstract]   [Full Text] [Related]  

  • 34. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C
    J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract]   [Full Text] [Related]  

  • 35. Progress with biological agents in metastatic colorectal cancer leads to many challenges.
    Van Cutsem E
    J Clin Oncol; 2006 Jul; 24(21):3325-7. PubMed ID: 16849745
    [No Abstract]   [Full Text] [Related]  

  • 36. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
    Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
    Gambill BD
    Clin Colorectal Cancer; 2001 May; 1(1):18-9. PubMed ID: 12445375
    [No Abstract]   [Full Text] [Related]  

  • 38. [Adjuvant therapy for colon cancer].
    Lordick F; Rosenberg R; Stein HJ; Peschel C; Siewert JR
    Dtsch Med Wochenschr; 2004 Oct; 129(44):2366-71. PubMed ID: 15497107
    [No Abstract]   [Full Text] [Related]  

  • 39. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
    [No Abstract]   [Full Text] [Related]  

  • 40. Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.
    Goffin JR; Talavera JR
    J Clin Oncol; 2006 Jan; 24(3):528-9; author reply 529-30. PubMed ID: 16421433
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.